Tackling osteoarthritis during COVID-19 pandemic

Ann Rheum Dis. 2021 Feb;80(2):151-153. doi: 10.1136/annrheumdis-2020-218372. Epub 2020 Sep 28.

Abstract

In this opinion article, we would like to draw attention to the fact that COVID-19 has a significant impact not only on immune-mediated arthritis but also on osteoarthritis (OA), the most common rheumatic disease. We suggest herein strategies for pain relief and symptom prevention in patients with OA during COVID-19 pandemic.

Keywords: analgesics; epidemiology; osteoarthritis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • COVID-19*
  • Disease Management
  • Exercise
  • Exercise Therapy*
  • Glucocorticoids / therapeutic use*
  • Humans
  • Hyaluronic Acid / therapeutic use
  • Injections, Intra-Articular
  • Osteoarthritis / therapy*
  • Pain Management
  • SARS-CoV-2
  • Viscosupplements / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Glucocorticoids
  • Viscosupplements
  • Hyaluronic Acid